Desmedt L K, Niemegeers C J, Janssen P A
Arzneimittelforschung. 1975 Sep;25(9):1408-13.
The anticonvulsive properties of orally administered cinnarizine [(E)-1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)-piperazine], its difluoro derivative flunarizine [(E)-1-(bis-(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)-piperazine], diphenylhydantoin and phenobarbital, were studied against maximal metrazol seizures (MMS) in rats and maximal electroshock seizures (MES) in mice. In rats (MMS), the lowest ED50 for protection against tonic extension of hindpaws was 4.10 mg/kg (1 h 35 min after treatment) with sodium phenobarbital, 6.04 mg/kg (5 h 45 min) with flunarizine dihydrochloride, 9.84 mg/kg (2 h 34 min) with cinnarizine and 19.30 mg/kg (3 h 38 min) with diphenylhydantoin. In mice (MES), protection against tonic extension of hindpaws was (2 h after treatment) 7.0 mg/kg with diphenylhydantoin, 13.2 mg/kg with sodium phenobarbital, 20.9 mg/kg with flunarizine kihydrochloride and 49.0 mg/kg with cinnarizine. Except at subtoxic doses no side effects were observed in rats and mice given cinnarizine, flunarizine kihydrochloride or kiphenylhydantoin. Phenobarbital induced ataxia in rats and mice at 22 mg/kg and 42.7 mg/kg, respectively, and loss of righting reflex at 112.8 mg/kg and 160 mg/kg, respectively. Flunarizine is the longest-acting drug and has the slowest onset. At a dose of twice the minimal ED50 flunarizine affords protection against tonic extension of hindpaws in rats (MMS) for 23 h 30 min dephenylhydantoin for 11 h 38 min, phenobarbital for 8 h 22 min and cinnarizine for 8 h 16 min. Peak effect was reached with flunarizine at 5 h 45 min, with diphenylhydantoin at 3 h 38 min, with cinnarizine at 2 h 34 min and with phenobarbital at 1 h 35 min. The anti-MMS profiles of cinnarizine and flunarizine resemble that of dephenylhydantoin as all three compounds are selective blockers of tonic extension of hindpaws. Phenobarbital antagonized the whole MMS-pattern, i.e., tremors, clonic convulsions and tonic extension of fore- and hindpaws. However, the effects of phenobarbital against tremors, clonic convulsions and tonic extension of forepaws may reflect more a general CNS-depressant effect than a specific anticonvulsive activity since neurotoxic effects (ataxia and loss of righting reflex) appear at the same doses.
研究了口服桂利嗪[(E)-1-(二苯甲基)-4-(3-苯基-2-丙烯基)-哌嗪]、其二氟衍生物氟桂利嗪[(E)-1-(双(4-氟苯基)甲基)-4-(3-苯基-2-丙烯基)-哌嗪]、苯妥英钠和苯巴比妥对大鼠最大戊四氮惊厥(MMS)和小鼠最大电休克惊厥(MES)的抗惊厥特性。在大鼠(MMS)中,预防后爪强直性伸展的最低半数有效剂量(ED50)为:苯巴比妥钠4.10mg/kg(治疗后1小时35分钟)、盐酸氟桂利嗪6.04mg/kg(5小时45分钟)、桂利嗪9.84mg/kg(2小时34分钟)、苯妥英钠19.30mg/kg(3小时38分钟)。在小鼠(MES)中,预防后爪强直性伸展的剂量为(治疗后2小时):苯妥英钠7.0mg/kg、苯巴比妥钠13.2mg/kg、盐酸氟桂利嗪20.9mg/kg、桂利嗪49.0mg/kg。给予桂利嗪、盐酸氟桂利嗪或苯妥英钠的大鼠和小鼠,除亚中毒剂量外未观察到副作用。苯巴比妥分别在22mg/kg和42.7mg/kg时使大鼠和小鼠出现共济失调,分别在112.8mg/kg和160mg/kg时使大鼠和小鼠出现翻正反射消失。氟桂利嗪是作用时间最长、起效最慢的药物。在两倍最小ED50剂量下,氟桂利嗪对大鼠(MMS)后爪强直性伸展的保护作用持续23小时30分钟,苯妥英钠为11小时38分钟,苯巴比妥为8小时22分钟,桂利嗪为8小时16分钟。氟桂利嗪在5小时45分钟达到最大效应,苯妥英钠在3小时38分钟,桂利嗪在2小时34分钟,苯巴比妥在1小时35分钟。桂利嗪和氟桂利嗪的抗MMS谱与苯妥英钠相似,因为这三种化合物都是后爪强直性伸展的选择性阻滞剂。苯巴比妥拮抗整个MMS模式,即震颤、阵挛性惊厥以及前爪和后爪的强直性伸展。然而,苯巴比妥对抗震颤、阵挛性惊厥和前爪强直性伸展的作用可能更多地反映了一种一般的中枢神经系统抑制作用,而非特异性抗惊厥活性,因为在相同剂量下会出现神经毒性作用(共济失调和翻正反射消失)。